HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Amgen’s Prolia/Xgeva Original Sales Close To $100m, mAbxience In Phase III
Executive Summary
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
You may also be interested in...
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Sandoz Maintains Lead On Denosumab As It Files With FDA
Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.
Russia’s Binnopharm Brings In Mabwell’s Adalimumab, Denosumab Biosimilars
China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.